Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 259 of 5804
-
Smart bomb for kidney cancer: imaging and radiation combo targets tough tumors
Disease control Recruiting nowThis is an open-label, multicenter, Phase 1a/1b study evaluating the theranostic pair 64Cu-PD-32766 Injection (PD-32766D) and 225Ac-PD-32766 Injection (PD-32766T) in adult patients with relapsed or refractory Carbonic Anhydrase IX (CA9)-expressing clear cell renal cell carcinoma …
Phase: PHASE1 • Sponsor: PeptiDream Inc. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug trial aims to tame seizures in rare childhood disorder
Disease control Not yet recruitingThis study will assess the efficacy, safety, and tolerability of ganaxolone (GNX) compared with placebo (PBO) as adjunctive therapy to the participant's standard anti-epileptic medication for the treatment of seizures in pediatric patients from 6 months to less than 2 years old w…
Phase: PHASE3 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Vulvar cancer study aims to spare women from unnecessary surgery
Disease control Not yet recruitingThis study is a phase III, open label, multicentre, three-group, randomised clinical trial. The primary aim of this study is to determine whether intensive groin ultrasound monitoring (1) is effective and safe to replace invasive groin lymph node dissection (LND) to manage vulvar…
Phase: PHASE3 • Sponsor: Queensland Centre for Gynaecological Cancer • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Engineered immune cells take on hard-to-treat breast cancer in new trial
Disease control Not yet recruitingThe purpose of this study is to find the biggest dose of HTR2 T cells that is safe, to see how long these cells last in the body, to learn the side effects, and to see if these cells are able to fight and kill HER2 expressing breast cancer. Patients eligible for this study have …
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
One-Time gene shot aims to mend broken hearts
Disease control Recruiting nowThis is a Phase 1, open-label, dose-escalation trial to characterize the safety, tolerability, and preliminary efficacy of RP-A701 following a single IV administration in high-risk adult patients with BAG3-DCM.
Phase: PHASE1 • Sponsor: Rocket Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for hard-to-treat blood cancers: phase 3 trial pits NX-5948 against standard therapy
Disease control Not yet recruitingThe study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinas…
Phase: PHASE3 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for Tough-to-Treat myeloma: phase 3 trial launches
Disease control Not yet recruitingThis study is a randomized, open-label, multicenter Phase III clinical trial involving patients with relapsed/refractory multiple myeloma. The estimated total sample size is 260 cases, who will be randomly assigned in a 1:1 ratio to the test group and the control group. The prima…
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug masitinib could slow Alzheimer's decline
Disease control Not yet recruitingMasitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). Study AB21004 will evaluate masitinib as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate Alzh…
Phase: PHASE3 • Sponsor: AB Science • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Immunotherapy plus chemo may open door to surgery for inoperable lung cancer
Disease control Not yet recruitingThis is a prospective, single-center phase II study evaluating sintilimab plus chemotherapy as induction therapy for unresectable stage IIIC non-small cell lung cancer (NSCLC). Treatment-naive eligible patients who signed informed consent were enrolled after MDT screening. Patien…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Blood thinners for stroke survivors with a history of brain bleeding: a delicate balance
Disease control Not yet recruitingThis prospective, multicenter, randomized controlled trial aims to evaluate the efficacy and safety of initiating direct oral anticoagulants (DOACs) in patients with a history of spontaneous intracerebral hemorrhage (ICH) and non-valvular atrial fibrillation (AF) who have recentl…
Phase: PHASE4 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug cocktail shows promise for Hard-to-Treat breast cancer before surgery
Disease control Not yet recruitingThis is a phase II, single-arm, prospective exploratory study to evaluate the efficacy and safety of neoadjuvant dalpiciclib (a CDK4/6 inhibitor) plus an aromatase inhibitor (AI) followed by SHR-A1811 (an anti-HER2 antibody-drug conjugate) in patients with intermediate-to-high ri…
Phase: PHASE2 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental gene therapy targets rare metabolic disease in toddlers
Disease control Recruiting nowPropionic acidemia is a genetic metabolic disorder characterized by metabolic acidosis, ketosis, vomiting, lethargy, cognitive impairment, and risk of death. It results from loss of function of the mitochondrial enzyme propionyl-CoA carboxylase and can be due to disease-causing v…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New probe technique could slash cervical cancer risk in HIV-Positive women
Prevention Not yet recruitingCervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the Wor…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
Could a simple aspirin boost brain recovery after aneurysm rupture?
Disease control Not yet recruitingThis study is a multicenter, prospective, double-blind, randomized controlled trial designed to evaluate whether early prophylactic use of aspirin improves functional outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH). Patients with aSAH who have undergone succes…
Phase: PHASE4 • Sponsor: Ganzhou City People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Painless blood test could replace bone marrow biopsy for MPN patients
Diagnosis Not yet recruitingThis observational, multi-center study aims to collect data to develop a novel, minimally invasive diagnostic tool for myeloproliferative neoplasms (MPN) based on peripheral blood (PB) profiling of circulating hematopoietic stem and progenitor cells (cHSPCs) using single-cell RNA…
Sponsor: Weizmann Institute of Science • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat solid tumors
Disease control Recruiting nowThe purpose of this clinical trial is to assess the feasibility, safety and efficacy of anti-GD2/PSMA bi-specific CAR-T cell therapy in patients with GD2 and PSMA positive tumor. Another goal of the study is to learn more about the function of the anti-GD2/PSMA bi-specific CAR-T …
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a pill replace the CPAP machine for sleep apnea?
Disease control Not yet recruitingThe goal of this randomized, double-blind, multi-dose crossover clinical trial is to determine the safety and efficacy of IHL-42X in subjects with obstructive sleep apnea. The primary endpoint is: Change in AHI4 at the end of each treatment period compared to baseline (each trea…
Phase: PHASE2 • Sponsor: Incannex Healthcare Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug targets inflammation in Hard-to-Treat Behçet's disease
Disease control TerminatedBehcet's syndrome (BS) is a multisystem autoimmune vasculitis. Current clinical treatment primarily includes glucocorticoids, immunosuppressants, and molecularly targeted drugs such as TNF-α and IL-6 inhibitors; however, some patients still respond poorly to existing treatment re…
Phase: PHASE2 • Sponsor: Liu Tian • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Precision radiotherapy targets rare breast tumors by genetic fingerprint
Disease control Not yet recruitingPhyllodes tumor (PT) of the breast is a rare fibroepithelial neoplasm, and the role of postoperative radiotherapy (PORT) remains controversial. Our team has previously established a molecular subtyping system for PT, classifying patients into four subtypes. Among them, the malign…
Phase: NA • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for breast cancer patients: extra targeted drug may clear remaining tumors
Disease control Not yet recruitingThis is a prospective, multi-center, single-arm, phase 2 exploratory study to evaluate the efficacy and safety of adding 4 cycles of Trastuzumab Rezetecan (T-DXh), an anti-HER2 antibody-drug conjugate, as continued neoadjuvant therapy in patients with early or locally advanced HE…
Phase: PHASE4 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC